Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Edoardo Pennesi, C. Michel Zwaan, Kathleen Pelletier et al.|Blood|2022

Cited by 3